Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma, Kaposi 1AIDS-related Kaposi sarcoma 1

Interventions

Zidovudine 9Doxorubicin 9Vincristine 6Bleomycin 6Interferon alpha-2 5Etoposide 5tecogalan 4Valganciclovir 4Semaxinib 4Liposomes 4Ritonavir 3Paclitaxel 3Nelfinavir 3Filgrastim 3Bevacizumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2sargramostim 2liposomal doxorubicin 2interferon alfa-n1 2Indinavir 2Docetaxel 2Didanosine 2Alitretinoin 2vesnarinone 1valspodar 1tocilizumab 1tin etiopurpurin 1pomalidomide 1pembrolizumab 1halofuginone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sarcoma, Kaposi × halofuginone × Clear all
NCT00064142 2013-06-05

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
30 enrolled
Sarcoma

AIDS-related Kaposi sarcoma, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡